Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data
Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data appeared first on GEN - Genetic Engineering and Biotechnology News .
Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data appeared first on GEN - Genetic Engineering and Biotechnology News .
This is a summary of the story. Read the full article at GEN — Genetic Engineering & Biotechnology News ↗